Purpose of Review <p>Cancer-induced bone pain is a frequent, debilitating complication seen in metastatic cancers and often poorly controlled with conventional analgesics. Radiopharmaceutical therapy offers a targeted pain relief with beta emitters providing sustained analgesia and alpha emitters offering potent cytotoxicity and survival benefits.</p> Recent Findings <p>Emerging agents such as Lu-EDTMP show promising pain palliation with manageable toxicity. Radiopharmaceutical therapy enables systemic treatment of bone metastases and reduces opioid dependence while complementing local therapies.</p> Summary <p>This review aims to summarize the mechanisms, clinical evidence, advantages, limitations, and future directions of radiopharmaceutical therapy in the management of cancer-induced bone pain</p>